Novartis looks to settle doc-bribery suit; CEO shares update on Zolgensma coverage
The Swiss drugmaker, which reported an otherwise upbeat second quarter, allocated a substantial reserve to settle bribery charges stemming from the suit.
Legal/Regulatory
J&J’s legal troubles mount
The company’s failed bid to have the Oklahoma opioid case tossed was followed this week by a reported criminal probe into its talcum baby powder.
Another Trump drug price proposal bites the dust
A proposal to end rebates negotiated by PBMs was pulled back by the White House on Thursday. It’s the second drug price idea to be scrapped this week.
Judge: HHS overstepped bounds issuing list price disclosure rule
The rule requiring drugmakers to state the price of treatments in DTC ads was set to go into effect on Tuesday.
Why opioid liability trial is a gut check for marketers
All eyes are on Oklahoma as the first state-level case seeking to assign liability for the opioid crisis. Here’s why pharma marketers should brace for change in its wake.
Opioid marketing under the microscope in day two of Oklahoma trial
A doctor who had been paid speaking and consulting fees by opioid manufacturers testified on Wednesday.
Oklahoma opioid trial begins; state and J&J deliver opening statements
Johnson & Johnson is the only remaining defendant after both Purdue Pharma and Teva reached settlements with the state.
American Addiction Centers suit claims trade group excluded it from search ads
The AAC said the National Association of Addiction Treatment Providers engaged in anti-competitive and defamatory practices.
Purdue Pharma reaches first opioid-related lawsuit settlement
Purdue is settling a lawsuit brought by Oklahoma for $270 million. It is facing more than 1,600 lawsuits nationwide.
National Cancer Institute head named acting FDA commissioner
FDA Commissioner Scott Gottlieb said last Tuesday that he’s planning to resign in a few weeks.
